Skip to content

Impact of a Hydromorphone-Ropivacaine Transversus Abdominis Plane Block on Postoperative Neurocognitive Disorders in Elderly Patients After Laparoscopic Colorectal Cancer Surgery

Impact of a Hydromorphone-Ropivacaine Transversus Abdominis Plane Block on Postoperative Neurocognitive Disorders in Elderly Patients After Laparoscopic Colorectal Cancer Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120884
Enrollment
Unknown
Registered
2026-03-20
Start date
2026-03-21
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Experimental group:Abdominal Transversus Plane Block Performed with Hydrocodone and Ropivacaine

Sponsors

Yibin Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. All participants provided written informed consent; 2. Aged 45 to 75 years; 3. American Society of Anesthesiologists (ASA) physical status classification I to III; 4. Scheduled for elective laparoscopic radical resection of colorectal cancer with an expected surgical duration of >=120 minutes; 5. Preoperative Barthel Index score =95.

Exclusion criteria

Exclusion criteria: 1. Patients with a confirmed preoperative diagnosis of dementia, a history of psychiatric disorders, or long-term use of antipsychotics or sedative-hypnotics; 2. Patients with a history of long-term opioid use, a history of drug/alcohol abuse, or addiction; 3. Patients with a history of stroke, sequelae of traumatic brain injury, severe cardiac, pulmonary, hepatic, or renal insufficiency, or coagulation disorders; 4. Patients with known allergies to the study drugs (hydromorphone, ropivacaine) or any other medications used during anesthesia; 5. Patients who received neoadjuvant radiotherapy, chemotherapy, targeted therapy, or other anti-tumor treatments prior to surgery (radiotherapy and chemotherapy are strong confounders for cognitive impairment); 6. Patients with severe hearing or visual impairments that prevent them from cooperating with the completion of the scale assessments.

Design outcomes

Primary

MeasureTime frame
Perioperative neurocognitive disorders (PND);

Secondary

MeasureTime frame
Mini-Mental State Examination (MMSE) score;Resting Visual Analogue Scale (VAS) pain score;Cumulative number of tramadol use after surgery;mean arterial pressure (MAP) ;Heart rate (HR);Time to first ambulation after surgery;Time to first flatus after surgery;Barthel Index score;Montreal Cognitive Assessment (MoCA) score ;15-Item Quality of Recovery Scale (QoR-15) score;

Countries

China

Contacts

Public ContactYi Chuanyun; Yu Deshui

Yibin Second People's Hospital

2051722635@qq.com+86 130 8654 4485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026